Mar 1, 2018 · Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT …

All manuscripts submitted to The Journal of Nuclear Medicine should be accompanied by a copyright disclosure statement in compliance with the Copyright Revision Act ...

Jan 1, 2025 · Prostate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates …

1008 Learning Objectives A standard for communication between image analysis and reporting software can improve reporting efficiency and workflow and minimize transcription errors that …

Oct 3, 2024 · Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy …

SNMMI. . . . . . . . . . . . . . . . . . . . . . . . . . . .Page 1 correlations between quantication and visual Volume criteria in PSMA PET: Unterrainer and fi ...

Below are the 2024 subscription prices for the monthly Journal of Nuclear Medicine (JNM) and the quarterly Journal of Nuclear Medicine Technology (JNMT). Shipping costs are included in the …

Jan 1, 2025 · Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by …

Jan 1, 2025 · Robert J.H. Miller, Krishna K. Patel, Jacek Kwiecinski, Leandro Slipczuk, Marc Dweck, David E. Newby, Panithaya Chareonthaitawee and Piotr Slomka

Oct 1, 2022 · The application of radiopharmaceutical therapy for the treatment of certain diseases is well established, and the field is expanding. New therapeutic radiopharmaceuticals have …